24 Hours Treatment With Alteplase in Patients With Ischemic Stroke
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The development of intravenous thrombolysis has greatly improved the rate of recanalization
and reperfusion in patients with acute ischemic stroke, increasing the proportion of patients
with good outcome and reduced mortality. The guideline recommends that patients with ischemic
stroke should be treated with intravenous thrombolysis within 4.5 hours. The latest
meta-analysis found that ischemic stroke with onset time of 4.5-9 hours with infarction core
volume <70ml, ischemic penumbra volume >10ml, and hypoperfusion volume / infarction core
volume >1.2 could be benefit from intravenous thrombolysis. The DAWN clinical trial has shown
that patients with ischemic stroke with large vessel occlusion with onset time of 6-24 hours
could be benefit from endovascular treatment after screening by multi-mode imaging.
Therefore, we hypothesize that patients with ischemic stroke with onset time of 4.5-24 hours
with a definite penumbra may also benefit from intravenous thrombolysis. The purpose of this
study is to explore whether the patients with ischemic stroke with onset time of 4.5-24 hours
can benefit from intravenous thrombolysis if they meet the standard of CT perfusion
screening.
Phase:
Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Fourth Affiliated Hospital of Zhejiang University, School of Medicine Huzhou Center Hospital Jiaxing People's Hospital Jiaxing Second Hospital Lishui Country People's Hospital Shaoxing People's Hospital Zhoushan People's Hospital